^
    Back
    Association details:
    Biomarker:PIK3CA E545K
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:dactolisib (RTB101) (mTOR inhibitor, PI3K inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    JAMA Otolaryngol Head Neck Surg
    Title:

    Response of Head and Neck Squamous Cell Carcinoma Cells Carrying PIK3CA Mutations to Select Targeted Therapies

    Excerpt:
    ...When treated with BEZ-235, H1047R-expressing cell lines showed increased sensitivity to inhibition compared with control, whereas those expressing E545K showed slightly increased sensitivity of unclear significance.
    DOI:
    10.1001/jamaoto.2015.0471